INmune Bio Investor Relations Material
Latest events
Q1 2025
INmune Bio
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from INmune Bio Inc
Access all reports
INmune Bio, Inc. is a clinical-stage immunotherapy company. The company focuses on reprogramming the patient's innate immune system to treat cancer, Alzheimer's disease and non-alcoholic steatohepatitis. It has several development programs, including INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation in their blood; XPro1595 for the treatment of Alzheimer's disease; LivNate to treat patients with non-alcoholic steatohepatitis; and Quellor for cytokine release syndrome and complications of COVID-19
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
INMB
Country
🇺🇸 United States